{"retracted":false,"update":{"timestamp":1404172800000,"doi":"10.1016/j.ygyno.2014.04.048","type":"err"},"doi":"10.1016/j.ygyno.2013.07.081","journal":"Gynecologic Oncology","publisher":"Elsevier BV","title":"Corrigendum to: “Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer” [Gynecol Oncol 131 (2013) 169–173]"}
